mRNA vaccines

Professor Colin Pouto

Monash University has received $5 million from the Victorian Government to manufacture the first Australian batch of a COVID-19 mRNA vaccine for clinical trials, using a vaccine candidate developed by researchers from the Monash Institute of Pharmaceutical Sciences (MIPS).

The funding is part of the Victorian Government’s mRNA Victoria, established to lead the development of mRNA industry capability and manufacturing in the state and to deliver on the Victorian Government’s $50 million commitment to establish mRNA vaccine and therapeutic manufacturing in Melbourne.

This investment highlights Monash University’s world-class capability in the field of mRNA therapeutics.

The MIPS COVID-19 mRNA vaccine first received funding in 2020 through a collaboration with the Doherty Institute. The two leading Melbourne institutes received a Medical Research Future Fund (MRFF) grant to commence the clinical trial process for their two vaccine candidates.

The team, led by Professor Colin Pouton, will work with a Melbourne-based manufacturing company to prepare their product for Phase 1 clinical trials.

Read more: